Are there real tesamorelin before-and-after photos?

Not in the literature. The published evidence is CT imaging of visceral fat, not photography. Photos attached to the compound online are marketing, not data.

How long did the changes take?

The primary endpoint was 26 weeks, with a 52-week extension. The roughly 15% visceral fat reduction refers to the 26-week scan.

Did the fat return after stopping?

Yes. In the extension phase, visceral fat re-accumulated in patients switched to placebo. Maintenance of the change required continued exposure.

Was this weight loss?

Not meaningfully. Body weight changed little; the reduction was specific to visceral fat, with subcutaneous fat largely unchanged. Tesamorelin dosage for that effect is covered separately.

Tesamorelin Before and After: What the Trials Measured

The short answer

In the trials, before and after meant CT imaging rather than photographs: visceral adipose tissue fell by roughly 15% over 26 weeks of 2mg daily tesamorelin against placebo, with IGF-1 rising. A 2014 JAMA study added liver-fat reductions. The changes reversed after discontinuation, and the whole record sits in HIV-associated lipodystrophy, not the general population.

Key facts

Measure: CT-scanned visceral adipose tissue
Change: Roughly 15% VAT reduction at 26 weeks
Comparator: Placebo, which gained fat
Subcutaneous fat: Largely unchanged
After stopping: Visceral fat re-accumulated
Liver fat: Reduced (Stanley, JAMA 2014)

Before and after, without photographs

Search results promise transformation photos; the literature contains none. The tesamorelin before and after record is computed tomography: a cross-sectional scan at the L4-L5 vertebrae before treatment and again at 26 weeks, with visceral adipose tissue measured in square centimetres. It is a better record than photographs, and a less dramatic one.

The numbers at 26 weeks

In the pooled phase 3 analysis, 2mg daily tesamorelin reduced visceral adipose tissue by roughly 15% over 26 weeks while placebo groups gained, with IGF-1 rising as the pharmacology predicts. Subcutaneous fat was largely unchanged, which is the finding that made the compound interesting: the effect was selective for the visceral depot rather than general weight loss. Total body weight moved little.

Research material referenced

Tesamorelin 5mg, third-party HPLC tested

Buy Tesamorelin · £32.99

What happened after stopping

The extension phase answered the question every before-and-after implies: patients re-randomised from tesamorelin to placebo saw visceral fat re-accumulate toward baseline, while those who continued maintained the reduction. The after picture, in other words, lasted exactly as long as the exposure. Any durable-transformation framing is contradicted by the trial that generated the numbers.

The liver fat addendum

In 2014 a randomised JAMA study extended the imaging inward: tesamorelin reduced liver fat alongside visceral fat in HIV-infected patients with abdominal fat accumulation. Same population logic, same instrument-based before and after, and the same caveat that none of it was measured in healthy general-population subjects.

Why this is not a product claim

Every number above comes from a prescription medicine trialled in HIV-associated lipodystrophy. Material sold here is laboratory research stock, outside any medical context, and nothing on this page suggests an outcome for any person. The trial record is summarised because researchers should read the primary sources, all three of which are linked below.

Frequently asked questions

Are there real tesamorelin before-and-after photos?: Not in the literature. The published evidence is CT imaging of visceral fat, not photography. Photos attached to the compound online are marketing, not data.
How long did the changes take?: The primary endpoint was 26 weeks, with a 52-week extension. The roughly 15% visceral fat reduction refers to the 26-week scan.
Did the fat return after stopping?: Yes. In the extension phase, visceral fat re-accumulated in patients switched to placebo. Maintenance of the change required continued exposure.
Was this weight loss?: Not meaningfully. Body weight changed little; the reduction was specific to visceral fat, with subcutaneous fat largely unchanged. Tesamorelin dosage for that effect is covered separately.

Continue researching

Peer-reviewed guides, comparators and matched reference materials.

Primary sources & clinical trials

Peer-reviewed research and registered trials from PubMed, ClinicalTrials.gov, PubChem, FDA and NIH. All links open in a new tab and point to the primary source, so every claim can be verified at origin.

UKP

Written and reviewed by

William Heath · Editor, UK Peptides research library

William Heath edits the UK Peptides research library. He is responsible for what is published here: every article is sourced to primary literature, every purity or identity statement traces to a signed third-party certificate for a specific lot, and corrections are made in place with the review date updated. No scientific or medical credentials are claimed on this site; the evidence is carried by the cited sources and the certificates, not by the byline.

How we write and check this content Report a factual error in this article

More Tesamorelin (GHRH Analogue) articles

← Back to Forum